Gary,
VVUS, has more news out today,
VIVUS Awarded Patent for Oral Treatment of Premature Ejaculation
March 17, 2000 09:28 AM
MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 17, 2000-- Protection Covers Oral Administration of a 5-HT3 Antagonist
VIVUS, Inc. VVUS today announced that the US Patent & Trademark Office has awarded the Company Patent No. 6,037,360, entitled, "Administration of 5-HT.sub.3 receptor antagonists to treat premature ejaculation."
This patent provides VIVUS with broad patent protection for oral administration of serotonin antagonists, specifically 5-HT3 antagonists, to treat premature ejaculation (PE) in men. The patent also covers treating PE by administering a 5-HT3 antagonist topically, transdermally or transurethrally.
"Premature ejaculation is considered to be one of the most common male sexual disorders, for which there currently is no approved medical treatment," stated Leland F. Wilson, president and CEO of VIVUS, Inc.
Mr. Wilson added that VIVUS is conducting a proof-of-concept, Phase II clinical study for the evaluation of oral compounds for the treatment of PE. "Receipt of the 5-HT3 antagonist patent provides the Company with protection for the development of this class of compounds," added Mr. Wilson.
VIVUS, Inc. is a leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. The Company developed and manufactures the drug MUSE(R) (alprostadil) and the medical device ACTIS(R), two innovations in the treatment of erectile dysfunction, also known as impotence. In December 1999, the Company filed a New Drug Application with the Food and Drug Administration for ALIBRA(R), its second-generation drug for the treatment of ED. VIVUS also has ongoing research and development programs in female sexual dysfunction, male erectile dysfunction and premature ejaculation.
This news release contains forward-looking statements that involve risks and uncertainties regarding VIVUS Inc.'s operations and future results. Please see the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
CONTACT: VIVUS, Inc. Barbara Clark, (650) 934-5200 ir@vivus.com www.vivus.com or Lippert/Heilshorn & Associates, Inc. Bruce Voss (bruce@lhai.com) Bonnie Feldman (bonnie@lhai.com) (310) 575-4848 Media Contact Elissa Grabowski (elissa@lhai.com) (212) 838-3777 www.lhai.com
............................................................
stock is up over a dallor today on this news, FWIW.
psn |
